HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yih-Shou Hsieh Selected Research

Hepatocellular Carcinoma (Hepatoma)

1/2015Corrigendum to "Terminalia catappa Exerts Antimetastatic Effects on Hepatocellular Carcinoma through Transcriptional Inhibition of Matrix Metalloproteinase-9 by Modulating NF-κB and AP-1 Activity".
11/2013Dioscin-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and ERK and JNK signaling pathways in human lung cancer cell lines.
7/2012Survivin T9809C, an SNP located in 3'-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma.
1/2012Autophagy inhibition enhances apoptosis induced by dioscin in huh7 cells.
1/2012Terminalia catappa Exerts Antimetastatic Effects on Hepatocellular Carcinoma through Transcriptional Inhibition of Matrix Metalloproteinase-9 by Modulating NF-κB and AP-1 Activity.
10/2008Immunochemical localization of protein kinase Calpha in the biopsies of human hepatocellular carcinoma.
2/2008Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells.
1/2008Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1.
1/2008Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis.
1/2008Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yih-Shou Hsieh Research Topics

Disease

53Neoplasms (Cancer)
06/2023 - 04/2002
25Neoplasm Metastasis (Metastasis)
06/2022 - 07/2004
16Anorexia
11/2019 - 04/2005
16Lung Neoplasms (Lung Cancer)
01/2018 - 04/2002
16Hepatocellular Carcinoma (Hepatoma)
01/2015 - 09/2003
11Mouth Neoplasms (Oral Cancer)
01/2020 - 06/2003
10Inflammation (Inflammations)
01/2021 - 06/2002
9Osteosarcoma (Osteogenic Sarcoma)
06/2022 - 06/2004
7Osteoarthritis
04/2008 - 01/2004
5Melanoma (Melanoma, Malignant)
01/2022 - 01/2011
5Squamous Cell Carcinoma of Head and Neck
01/2020 - 06/2003
5Renal Cell Carcinoma (Grawitz Tumor)
11/2019 - 10/2011
5Carcinoma (Carcinomatosis)
11/2019 - 04/2005
4Lewis Lung Carcinoma
01/2018 - 01/2007
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2014 - 10/2007
4Carcinogenesis
10/2007 - 05/2007
4Arthritis (Polyarthritis)
06/2006 - 01/2004
3Breast Neoplasms (Breast Cancer)
08/2010 - 06/2004
3Pelvic Inflammatory Disease (Pelvic Inflammatory Diseases)
11/2009 - 01/2008
3Necrosis
03/2009 - 11/2002
3Knee Osteoarthritis
01/2008 - 05/2004
3Gouty Arthritis
06/2006 - 01/2004
3Periodontal Diseases (Periodontal Disease)
06/2004 - 06/2002
3Prostatic Neoplasms (Prostate Cancer)
09/2003 - 05/2002
2Liver Neoplasms (Liver Cancer)
06/2023 - 02/2008
2Colonic Neoplasms (Colon Cancer)
12/2019 - 10/2007
2Kidney Neoplasms (Kidney Cancer)
11/2019 - 01/2017
2Adenocarcinoma of Lung
01/2018 - 07/2015
2Body Weight (Weight, Body)
01/2018 - 01/2017
2Leukemia
01/2014 - 02/2009

Drug/Important Bio-Agent (IBA)

26Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
06/2023 - 07/2004
26Matrix Metalloproteinases (MMPs)IBA
06/2023 - 06/2002
24Matrix Metalloproteinase 2 (Gelatinase A)IBA
10/2019 - 02/2002
13Plasminogen Activators (Plasminogen Activator)IBA
06/2023 - 07/2004
13Peptide Hydrolases (Proteases)FDA Link
06/2023 - 07/2006
13Matrix Metalloproteinase 9 (Gelatinase B)IBA
01/2015 - 07/2002
10Messenger RNA (mRNA)IBA
07/2011 - 09/2003
10GelatinasesIBA
04/2008 - 06/2003
9GelatinIBA
10/2017 - 06/2003
8Proteins (Proteins, Gene)FDA Link
06/2022 - 06/2002
8Transcription Factor AP-1 (Transcription Factor AP 1)IBA
11/2019 - 05/2007
7EnzymesIBA
08/2010 - 03/2003
6Protein Kinase CIBA
10/2008 - 06/2002
6FibrinolysinFDA Link
04/2008 - 05/2003
5PhytochemicalsIBA
11/2019 - 12/2013
5Tissue Inhibitor of Metalloproteinase-2IBA
09/2013 - 07/2002
5Antisense OligonucleotidesIBA
05/2008 - 01/2007
5CytokinesIBA
01/2008 - 06/2002
4p38 Mitogen-Activated Protein KinasesIBA
06/2023 - 05/2007
4Focal Adhesion Protein-Tyrosine KinasesIBA
06/2022 - 05/2007
4AntioxidantsIBA
01/2021 - 01/2015
4FlavonoidsIBA
08/2017 - 01/2007
4PolyphenolsIBA
01/2013 - 01/2005
4Silybin (Lagosa)IBA
10/2011 - 07/2004
4Carbonic Anhydrases (Carbonic Anhydrase)IBA
08/2010 - 09/2003
4Cystatin CIBA
02/2009 - 03/2004
4Protein Kinases (Protein Kinase)IBA
10/2008 - 04/2007
4Protein Kinase C-alphaIBA
02/2008 - 09/2005
4Indicators and Reagents (Reagents)IBA
02/2008 - 01/2005
4BerberineIBA
12/2007 - 11/2002
4Mitogen-Activated Protein KinasesIBA
10/2007 - 10/2005
3CateninsIBA
01/2022 - 05/2014
3Reactive Oxygen Species (Oxygen Radicals)IBA
11/2019 - 10/2007
3thymoquinoneIBA
11/2019 - 01/2014
3Cytostatic AgentsIBA
10/2019 - 11/2016
3dioscinIBA
01/2017 - 01/2012
3Pro-Opiomelanocortin (Proopiomelanocortin)IBA
01/2015 - 03/2012
32'-hydroxyflavanoneIBA
01/2014 - 01/2007
3FlavanonesIBA
01/2014 - 01/2007
3NF-kappa B (NF-kB)IBA
06/2013 - 01/2008
3naringinIBA
09/2012 - 01/2007
3IsoenzymesIBA
07/2007 - 01/2005
3Anthocyanins (Anthocyanin)IBA
11/2006 - 01/2005
2GossypolIBA
01/2021 - 12/2019
2Cadherins (E-Cadherin)IBA
01/2020 - 05/2014
2Amphetamine (Amfetamine)FDA LinkGeneric
01/2018 - 07/2014
2DNA (Deoxyribonucleic Acid)IBA
01/2018 - 04/2002
2kaempferolIBA
01/2017 - 01/2013
2Cyclin BIBA
01/2017 - 01/2007
2abietic acidIBA
01/2017 - 01/2015
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2016 - 06/2004
2epicatechin gallateIBA
08/2016 - 09/2012
2Paclitaxel (Taxol)FDA LinkGeneric
01/2015 - 10/2011
2PaxillinIBA
12/2013 - 08/2012
2Appetite Depressants (Anorectics)IBA
11/2013 - 01/2007
2Anti-Obesity Agents (Antiobesity Drugs)IBA
11/2013 - 08/2010
2Tissue Inhibitor of Metalloproteinase-1IBA
09/2013 - 02/2002
2Neuropeptide YIBA
06/2013 - 01/2008
2Phenylpropanolamine (Dexatrim)FDA Link
06/2013 - 01/2008
2Gallic AcidIBA
09/2012 - 02/2009
2ProstaglandinsIBA
09/2010 - 03/2003
2peonidin 3-glucosideIBA
01/2010 - 01/2005
2Hemoglobins (Hemoglobin)IBA
01/2009 - 01/2007
2CreatinineIBA
04/2008 - 04/2006
2ImmunosorbentsIBA
04/2008 - 08/2007

Therapy/Procedure

10Therapeutics
01/2012 - 02/2003
6Drug Therapy (Chemotherapy)
01/2019 - 07/2015
3Oral Administration
06/2022 - 05/2007
3Traditional Medicine (Folk Remedies)
10/2019 - 04/2010
2Intraventricular Infusions
01/2015 - 01/2007